Genitourinary Cancer

Top Story

VIDEO: Pembrolizumab represents ‘important option’ for metastatic urothelial cancer

June 25, 2017

CHICAGO — Improvements in response duration and side effect profile seen in the KEYNOTE-045 trial of pembrolizumab establish this therapy “as a standard of care” for patients with previously treated, metastatic urothelial cancer, according to Matthew Galsky, MD, professor of medicine (hematology and medical oncology) and urology at the Icahn School of Medicine at Mount Sinai Hospital in New York.

Failed confirmatory trial raises questions about atezolizumab for advanced urothelial cancer

HemOnc Today, June 25, 2017
The future of atezolizumab as second-line treatment for urothelial cancer is in question after results of a confirmatory trial indicated the agent failed to extend…

Geneticist to lead Vanderbilt cancer center’s health disparities program

June 19, 2017
Tuya Pal, MD, has been appointed associate director of cancer health disparities at Vanderbilt-Ingram Cancer Center. Pal, a clinical geneticist, also will serve as…

10 highlights from the ASCO Annual Meeting

June 16, 2017
This year’s ASCO Annual Meeting, held June 2-6 in Chicago, featured the theme “Making a Difference in Cancer Care With You.” HemOnc Today
CME

Breakthroughs in the Treatment of Bladder Cancer

This activity is supported by an educational grant from Bristol-Myers Squibb.

Assessment of immune checkpoint blockade inhibitors in the treatment of bladder cancer have demonstrated significant…
More »
Video
Meeting News Coverage

VIDEO: CABOSUN trial ‘changes the game’ of first-line renal cell carcinoma therapy

October 12, 2016
More »
Featured
ASCO Annual Meeting

ASCO Annual Meeting

CME

Immune Checkpoint Inhibitors for Advanced Bladder Cancer: Applying Clinical Advances and Elucidating Best Practices

This activity is supported by an educational grant from Merck & Co, Inc.

Advances in immunology and the advent of immune checkpoint blockade inhibition for advanced bladder cancer are poised…
More »
Meeting NewsVideo

VIDEO: Pembrolizumab represents ‘important option’ for metastatic urothelial cancer

June 25, 2017
CHICAGO — Improvements in response duration and side effect profile seen in the KEYNOTE-045 trial of pembrolizumab establish this therapy…

Failed confirmatory trial raises questions about atezolizumab for advanced urothelial cancer

HemOnc Today, June 25, 2017
The future of atezolizumab as second-line treatment for urothelial cancer is in question after results of a confirmatory trial indicated the agent…

Geneticist to lead Vanderbilt cancer center’s health disparities program

June 19, 2017
Tuya Pal, MD, has been appointed associate director of cancer health disparities at Vanderbilt-Ingram Cancer Center. Pal, a clinical geneticist…

10 highlights from the ASCO Annual Meeting

June 16, 2017
This year’s ASCO Annual Meeting, held June 2-6 in Chicago, featured the theme “Making a Difference in Cancer Care With You.” …

Seattle Cancer Care Alliance among first to apply multispecialty care approach to kidney cancer

June 14, 2017
Seattle Cancer Care Alliance opened its multispecialty clinic specifically for kidney cancer patients in April, one of the first-of-its-kind in the…

Oral contraceptive use does not increase long-term cancer risk

June 14, 2017
Women who used oral contraceptives did not demonstrate increased long-term cancer risk, according to results of the Royal College of General…

Meeting NewsVideo

VIDEO: Visiting expert program helps community providers learn about immuno-oncology

June 12, 2017
CHICAGO — Jarushka Naidoo, MBBCh, spoke with HemOnc Today at the ASCO Annual Meeting about the Institute for Clinical Immuno-Oncology. The…

FDA News

FDA rejects Coherus application for proposed biosimilar to Neulasta

June 12, 2017
The FDA denied approval of Coherus BioSciences’ biologics license application for CHS-1701, a proposed biosimilar for pegfilgrastim. Like…

Lineberger Comprehensive Cancer Center director to lead NCI

June 12, 2017
President Donald J. Trump selected Norman E. “Ned” Sharpless, MD, to serve as director of NCI. Sharpless — recognized for his…

Primary NSCLC may be underdiagnosed among patients with metastatic renal cell carcinoma

June 9, 2017
More than 3% of patients with kidney cancer that metastasized to the lungs subsequently were found to have primary lung cancer, according to results…

More Headlines »
Advertisement
Advertisement